CAIRO: Members of the National Committee for the Control of Viral Hepatitis (NCCVH) met Wednesday to discuss the guidelines of the usage of Solvadi, a new therapy for hepatitis C to be administered to 50,000 patients, Youm7 reported.
During the meeting, NCCVH member Dr. Gamal Esmat said the registration process of patients at the NCCVH’s 26 centers nationwide will start in early August following Eid al-Fitr.
The action aims at identifying the cases that will receive priority treatment, said Minister of Health Adel Adawy, who added that the ministry plans to treat 50,000 patients with the new drug.
Former Assistant Minister of Health Dr. Abdel Hamid Abaza said the active ingredient of the Soldavi drug sold in Egypt is similar to that of its counterpart in the U.S. He also reassured that the film coated tablet of Solvadi comes in either yellow or white colors.
Sovaldi was introduced to Egypt earlier this year but the company that produced it was criticized over the drug’s prohibitively high price: $900 for a 12-week course of treatment. In May, the company offered to supply the therapy for 99 percent discount.
Additional reporting by Amal Allam.